Sourcing high-purity follistatin peptide online requires rigorous analytical verification, complete batch traceability, and strict adherence to laboratory-grade quality standards. PX1 Research supplies high-purity, USA-manufactured Follistatin dedicated exclusively to in vitro and preclinical research applications.
Sourcing high-purity follistatin peptide online requires rigorous analytical verification, complete batch traceability, and strict adherence to laboratory-grade quality standards. PX1 Research supplies high-purity, USA-manufactured Follistatin dedicated exclusively to in vitro and preclinical research applications.
Sourcing high-purity follistatin peptide online for laboratory research requires selecting suppliers that provide verified analytical documentation, including lot-specific High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) analysis. Research-grade Follistatin is an autocrine glycoprotein utilized in preclinical assays to investigate Transforming Growth Factor-beta (TGF-β) signaling, myostatin inhibition, and cellular differentiation pathways.
When evaluating options for acquiring follistatin peptide online, primary investigators and laboratory procurement managers must prioritize chemical purity, sequence fidelity, and low endotoxin levels. Substandard reagents containing residual trifluoroacetic acid (TFA), organic solvents, or bacterial endotoxins can confound cell culture viability assays and yield irreproducible signaling data. PX1 Research provides fully characterized, USA-manufactured research peptides designed to satisfy the rigorous baseline requirements of controlled laboratory environments.
Follistatin (FST) is a monomeric, cysteine-rich autocrine glycoprotein originally isolated from porcine follicular fluid. It is encoded by a single gene located on chromosome 5 in humans, which undergoes alternative splicing to generate distinct protein isoforms. The precursor pre-protein consists of a signal peptide, an N-terminal domain (ND), three follistatin domains (FSD1, FSD2, and FSD3), and a C-terminal region.
Alternative splicing at the 3' end of the primary transcript produces two primary mRNA variants: Follistatin-315 (FST-315) and Follistatin-288 (FST-288). FST-315 represents the primary circulating isoform in vivo, featuring an extended acidic C-terminal tail that masks its basic heparin-binding sequence. Upon tissue targeted proteolytic cleavage, FST-315 can convert to Follistatin-300 (FST-300). Conversely, FST-288 lacks the acidic C-terminal tail, exposing a high-affinity heparin-binding domain that facilitates strong electrostatic interactions with cell-surface heparan sulfate proteoglycans (HSPGs).
A synthetic recombinantly expressed or peptide fragment variant widely utilized in exploratory protocols is Follistatin-344 (FST-344), which functions as a precursor transcript containing the full 344-amino-acid sequence prior to post-translational signal peptide cleavage. In experimental settings documented in our research library hub, these distinct structural configurations dictate tissue retention rates, systemic clearance kinetics, and localized binding affinities to extracellular matrix components.
The primary biochemical function of Follistatin in cellular models involves high-affinity binding to specific members of the Transforming Growth Factor-beta (TGF-β) superfamily of signaling proteins. Most notably, Follistatin binds to Activin A, Activin B, Myostatin (Growth Differentiation Factor 8 / GDF-8), and Growth Differentiation Factor 11 (GDF-11).
Follistatin neutralizes these ligands by forming an irreversible non-covalent stoichiometry complex. Two Follistatin molecules wrap around a single dimeric ligand molecule, such as Myostatin or Activin A. The N-terminal domain and FSD1/FSD2 regions of Follistatin physically occlude both Type I and Type II receptor-binding sites on the ligand dimer. By preventing the ligand from engaging Activin Type IIA or Type IIB receptors (ActRIIA/ActRIIB), Follistatin blocks downstream receptor dimerization and the subsequent phosphorylation of intracellular Smad proteins (specifically Smad2 and Smad3).
In uninhibited control models, phosphorylated Smad2/3 forms a heterotrimeric complex with Smad4, which translocates to the nucleus to induce transcription of genes that suppress muscle protein synthesis and promote extracellular matrix deposition. By arresting Smad2/3 activation, Follistatin facilitates an environment where positive regulators of muscle mass, such as the Akt/mTOR (mammalian target of rapamycin) cascade, operate without negative feedback constraints. Investigating these regulatory cascades remains a central focus of myostatin inhibition pathways literature.
In vitro data and rodent preclinical models consistently demonstrate that native and recombinant Follistatin administration leads to marked alterations in skeletal muscle architecture. In murine models of muscular dystrophy and age-related sarcopenia, transgenic overexpression or localized delivery of Follistatin leads to significant increases in cross-sectional muscle fiber area (hypertrophy) as well as the generation of new myofibers (hyperplasia).
Preclinical studies suggest that Follistatin-mediated myostatin blockade enhances the activation, proliferation, and fusion of satellite cells—the resident stem cells of skeletal muscle tissue—to existing damaged myofibers. This activity accelerates functional recovery following mechanical strain or ischemic injury models. Furthermore, because Follistatin inhibits both Myostatin and Activin A simultaneously, its phenotypic effect on muscle mass expansion frequently exceeds that of isolated anti-myostatin monoclonal antibodies, as Activin A acts redundantly to compensate when myostatin alone is neutralized.
Beyond skeletal muscle hypertrophy, animal studies indicate that Follistatin plays a protective role in limiting muscle atrophy induced by glucocorticoid exposure, joint immobilization, and systemic inflammatory cytokine cascades. These observations make research-grade Follistatin a valuable reagent for exploring molecular targets in metabolic disease, muscle wasting syndromes, and cachexia models.
In addition to its role in skeletal muscle regulation, Follistatin is heavily investigated for its anti-fibrotic properties across diverse organ systems. Activin A is a key driver of pathological fibrosis, driving fibroblast proliferation, myofibroblast differentiation, and excessive collagen deposition in renal, hepatic, pulmonary, and cardiac tissues.
In vitro assays using cultured human dermal and pulmonary fibroblasts indicate that exposure to Follistatin attenuates TGF-β1- and Activin A-induced expression of alpha-smooth muscle actin (α-SMA), fibronectin, and type I collagen. Animal studies investigating liver fibrosis models demonstrate that Follistatin administration attenuates hepatic stellate cell activation, thereby reducing extracellular matrix accumulation and preserving tissue architecture.
In renal tissue models, recombinant Follistatin delivery has been observed to mitigate tubulointerstitial fibrosis following chronic ischemia-reperfusion injury. Researchers measuring matrix metalloproteinase (MMP) activity and tissue inhibitors of metalloproteinases (TIMPs) frequently utilize Follistatin to delineate the specific contributions of Smad-dependent versus Smad-independent pathways in cellular matrix turnover.
When designing preclinical assays targeting muscle hypertrophy or tissue repair, researchers often compare Follistatin against other compounds in our all peptides catalog that influence growth factor signaling or tissue regeneration. Understanding the operational differences between these target mechanisms is crucial for experimental design.
Follistatin directly sequesters TGF-β superfamily ligands extracellularly, acting upstream of membrane-bound receptors. In contrast, target compounds like ACVR2B-Fc function as soluble decoy receptors consisting of the extracellular domain of the Activin receptor type IIB fused to an Fc antibody domain. While both approaches neutralize Myostatin and Activin A, ACVR2B-Fc exhibits a distinct binding profile that includes Bone Morphogenetic Proteins (BMP-9 and BMP-10), which can alter vascular endothelial responses in animal models. Meanwhile, peptides like IGF-1 LR3 stimulate skeletal muscle growth via an entirely separate axis—activating the IGF-1 receptor and intracellular receptor tyrosine kinase pathways rather than inhibiting Smad signaling. For tissue repair models, researchers may also contrast Follistatin's extracellular anti-fibrotic activity with the cytoprotective, non-homogenous repair signaling observed with BPC-157.
Procuring research compounds online introduces strict requirements for analytical verification. Because recombinant proteins and synthetic peptides are susceptible to aggregation, truncation, and chemical degradation during synthesis and purification, non-validated reagents can lead to inconsistent assay results or total experimental failure.
PX1 Research enforces comprehensive analytical quality control protocols for every batch of follistatin peptide online:
1. **Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC):** Used to confirm chemical purity. Every lot must achieve a minimum purity threshold of ≥98.0%, verified by sharp, isolated peak profiles without secondary degradation peaks. 2. **Electrospray Ionization Mass Spectrometry (ESI-MS):** Validates precise molecular mass, verifying target amino acid sequence identity and ensuring the absence of deletion sequences or incomplete synthesis fragments. 3. **Bacterial Endotoxin Testing:** Performed via Limulus Amebocyte Lysate (LAL) chromogenic assay to guarantee endotoxin levels remain below 0.01 EU/mg, protecting delicate cell culture models from endotoxin-induced toll-like receptor (TLR4) activation. 4. **Batch Traceability and ISO 17025 Testing:** Every product includes a lot-specific Certificate of Analysis (COA) issued by an independent ISO 17025 accredited laboratory, manufactured in domestic, GMP-compliant facilities.
To preserve structural integrity and biological activity, research-grade Follistatin must be handled according to strict physical laboratory parameters. The lyophilized peptide is stable at room temperature for brief periods during transit but must be stored immediately upon receipt at -20°C or -80°C in a manual defrost freezer.
Reconstitution should be conducted using sterile, laboratory-grade solvents under a laminar flow hood. For long-term stability in liquid suspension, researchers typically reconstitute the lyophilized powder in sterile Bacteriostatic Water or sterile phosphate-buffered saline (PBS, pH 7.4) supplemented with 0.1% Bovine Serum Albumin (BSA) or Human Serum Albumin (HSA). The addition of a carrier protein prevents non-specific adsorption of the peptide to the hydrophobic walls of polypropylene microcentrifuge tubes.
Following initial reconstitution, the solution should be aliquoted into single-use experimental volumes to avoid repeated freeze-thaw cycles, which induce protein denaturation and aggregation. Detailed calculations for volumetric preparation can be established using our peptide reconstitution calculator. Reconstituted aqueous solutions stored at 4°C should typically be utilized within 7 to 14 days.
PX1 Research is dedicated to supplying the scientific community with reliable, highly characterized research compounds manufactured in the United States. Laboratories procuring follistatin peptide online through PX1 Research benefit from full transparency, lot-specific COAs downloadable directly from our portal, and rigorous quality assurance protocols.
Orders placed Monday through Friday ship same-day from our dual fulfillment centers in California and Arizona, ensuring minimal transit times and preservation of cold-chain integrity when required. Whether conducting preliminary in vitro screening or large-scale institutional projects through our wholesale lab account portal, PX1 Research maintains the analytical standards necessary to support repeatable, peer-reviewable research.
What is the primary mechanism of Follistatin in preclinical research?
Follistatin acts as an autocrine glycoprotein that binds directly and irreversibly to TGF-β superfamily ligands, primarily Myostatin (GDF-8) and Activin A. This binding prevents ligand engagement with ActRIIA/ActRIIB receptors, inhibiting downstream Smad2/3 phosphorylation and transcription.
How is the purity of Follistatin verified by PX1 Research?
PX1 Research verifies every lot using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm ≥98% purity, and Mass Spectrometry (MS) to confirm exact molecular weight. Each lot undergoes independent testing in an ISO 17025 accredited third-party laboratory.
What are the endotoxin limits for PX1 Research Follistatin?
All research peptides supplied by PX1 Research undergo LAL chromogenic assay testing to ensure bacterial endotoxin levels remain under 0.01 EU/mg, preventing artifacts in sensitive in vitro and cell culture assays.
How should lyophilized Follistatin be stored upon arrival?
Upon receipt, lyophilized Follistatin should be stored at -20°C or -80°C in a dry environment. Desiccated storage prevents moisture accumulation and structural degradation of the peptide matrix.
What is the recommended solvent for reconstituting Follistatin for lab use?
Follistatin is typically reconstituted in sterile phosphate-buffered saline (PBS, pH 7.4) or sterile water containing 0.1% carrier protein (such as BSA or HSA) to prevent non-specific binding to container walls.
What is the structural difference between Follistatin 344 and Follistatin 315?
Follistatin-344 represents the precursor transcript before signal peptide processing. Follistatin-315 is the primary circulating isoform in vivo, featuring a C-terminal region that modulates its tissue-binding affinity compared to shorter, tissue-bound variants like FST-288.
Is Follistatin approved for human consumption or medical use?
No. Follistatin supplied by PX1 Research is strictly sold as a research compound for in vitro, cellular, and preclinical laboratory investigation. It is not for human or veterinary use, therapy, or clinical administration.
How quickly does PX1 Research dispatch online peptide orders?
PX1 Research dispatches all orders placed Monday through Friday same-day. Shipments originate from dispatch facilities located in California and Arizona to ensure fast delivery to domestic research institutions.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.